시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 편평부염 치료 시장 보고서(2025년)
Pars Planitis Treatment Global Market Report 2025
상품코드 : 1769702
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,263,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,052,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,842,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

편평부염 치료 시장 규모는 향후 수 년간 강력한 성장이 예상됩니다. 대규모, 개인화된 치료 접근법에 대한 수요 증가로 인해, 이 기간에 예상되는 주요 동향으로는 스테로이드를 온존하는 치료법으로 이동, 환자 관리에서의 원격 안과의 통합, 장시간 작용형 약물 임플란트의 개발, 치료에 있어서의 biosimilars의 사용, 병용 치료 전략에 대한 기호 증가 등이 있습니다.

편평부염의 유병률 상승이 편평부염 치료 시장의 성장을 견인할 것으로 예측됩니다. 포도막염의 일종으로, 15-40세가 가장 많이 영향을 받습니다. 유병률의 증가는 진단 기술의 인식 개선 및 발전과 관련이 있으며, 이는 더 빠르고 정확한 발견을 가능하게 합니다. 편평부염에 대한 치료는 안구의 염증을 관리하고 시력을 유지하고 심각한 합병증을 예방하기 위해 필수적입니다. Mega Journal of Case Reports'가 2025년 2월에 발표한 사례보고에 따르면, 중간 포도막염은 인구 10만명당 1.4-2건의 비율로 발생하며, 그 70%를 편평부염이 차지하고 있습니다.

편평부염 치료 영역의 기업은 염증의 제어를 개선하고 전신적인 부작용을 줄이기 위해 이중 특이성 항체를 포함한 고급 치료법의 개발에 주력하고 있습니다. 2023년 10월 미국 바이오테크놀러지 기업인 제넨텍은 노화 황반 변성과 당뇨병 황반 부종에 대한 선행 승인 외에도 망막 정맥 폐색증 치료제 Vabysmo (faricimab-svoa)의 FDA 승인을 받았습니다. Vabysmo는 Angiopoietin-2(Ang-2)와 혈관 내피 성장 인자 A(VEGF-A)를 모두 표적으로 하는 안과용으로 승인된 최초의 이중특이 항체입니다. 이 이중 작용 접근법은 염증과 혈관 누출을 통제하는 것을 돕고, 망막 주변의 지속적인 염증이 정확한 개입을 필요로 하는 편평부염을 포함하는 중간 포도막염의 치료제로 연구되고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

Pars planitis treatment involves both medical and surgical approaches designed to manage this chronic form of intermediate uveitis, which affects the pars plana region of the eye and may lead to inflammation and potential vision loss. The main objective of treatment is to control ocular inflammation, prevent complications such as macular edema or retinal detachment, and maintain visual function.

The primary treatment options for pars planitis include corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), surgical procedures, cryotherapy, immunomodulatory therapies, and others. Corticosteroids are anti-inflammatory drugs that mimic adrenal gland hormones to reduce swelling, suppress immune activity, and treat inflammation-related conditions. Diagnostic methods include blood tests, X-rays, magnetic resonance imaging (MRI), and others, with treatments administered via oral, intravenous, and other routes. These treatments are distributed through various channels, such as hospital pharmacies, retail pharmacies, and online pharmacies, and are used by a range of end users including hospitals, clinics, and other healthcare facilities.

The pars planitis treatment market research report is one of a series of new reports from The Business Research Company that provides pars planitis treatment market statistics, including the pars planitis treatment industry's global market size, regional shares, competitors with an pars planitis treatment market share, detailed pars planitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the pars planitis treatment industry. This pars planitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pars planitis treatment market size has grown strongly in recent years. It will grow from $632.88 billion in 2024 to $683.54 billion in 2025 at a compound annual growth rate (CAGR) of 8.0%. The growth during the historic period can be attributed to increased awareness of autoimmune eye disorders, a rising incidence of uveitis in pediatric populations, improved access to ophthalmic care, broader use of immunosuppressive therapies, and heightened patient awareness regarding the importance of early intervention.

The pars planitis treatment market size is expected to see strong growth in the next few years. It will grow to $920.48 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth anticipated in the forecast period can be attributed to the increasing adoption of biologic therapies, a rising prevalence of autoimmune diseases, heightened emphasis on pediatric eye care, broader health insurance coverage, and growing demand for personalized treatment approaches. Key trends expected during this period include a shift toward steroid-sparing treatment options, the integration of teleophthalmology in patient management, the development of long-acting drug implants, the use of biosimilars in therapy, and a rising preference for combination treatment strategies.

The rising prevalence of pars planitis is expected to drive the growth of the pars planitis treatment market. Pars planitis is an idiopathic type of intermediate uveitis that causes inflammation in the vitreous and peripheral retina, most commonly affecting people between the ages of 15 and 40. The increase in prevalence is linked to improved awareness and advancements in diagnostic technology, allowing for earlier and more accurate detection. Treatments for pars planitis are essential for managing ocular inflammation, which helps preserve vision and prevent serious complications. These therapies, which include corticosteroids and immunosuppressants, contribute to better long-term eye health and quality of life. As an example, a case report published in February 2025 by the Mega Journal of Case Reports, a U.S.-based medical journal, noted that intermediate uveitis occurs at a rate of 1.4 to 2 cases per 100,000 people, with pars planitis making up 70% of those cases. This increasing occurrence is contributing to the expansion of the treatment market.

Companies in the pars planitis treatment space are focusing on developing advanced therapies, including bispecific antibodies, to improve inflammation control and reduce systemic side effects. Bispecific antibodies are engineered to bind to two different antigens at once, allowing for more targeted and effective treatment. In October 2023, Genentech Inc., a biotechnology company based in the U.S., received FDA approval for Vabysmo (faricimab-svoa) for treating retinal vein occlusion, in addition to its earlier approvals for age-related macular degeneration and diabetic macular edema. Vabysmo is the first bispecific antibody approved for ophthalmic use, targeting both Angiopoietin-2 (Ang-2) and vascular endothelial growth factor A (VEGF-A). This dual-action approach helps control inflammation and vascular leakage and is being investigated for treating intermediate uveitis, including pars planitis, where persistent inflammation in the retinal periphery requires precise intervention.

In March 2022, Bausch + Lomb, a healthcare company headquartered in Canada, entered into a partnership with Clearside Biomedical Inc. to commercialize XIPERE in the U.S. for treating macular edema linked to uveitis. The goal of the partnership is to broaden access to XIPERE, which is the first FDA-approved therapy administered via suprachoroidal injection. This delivery method offers a targeted and effective option for the estimated 300,000 Americans affected by uveitis. Clearside Biomedical Inc., based in the U.S., contributes to pars planitis treatment through its involvement with XIPERE.

Major players in the pars planitis treatment market are Johnson & Johnson, Merck & Co Inc., AbbVie Inc., Bayer AG, AstraZeneca plc, Novartis AG, EyePoint Pharmaceuticals Inc., Medtronic plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Quantum Cryogenics Ltd., Zimmer MedizinSysteme GmbH, Sun Pharmaceutical Industries Ltd., Hologic Inc., Aurobindo Pharma Limited, Santen Pharmaceutical Co. Ltd., CooperSurgical Inc., AtriCure Inc., Alimera Sciences Inc., and Clearside Biomedical Inc.

North America was the largest region in the pars planitis treatment market in 2024. The regions covered in pars planitis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pars planitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pars planitis treatment market consists of revenues earned by entities by providing services such as diagnosis, pharmacological therapies, surgical interventions, and supportive care management. The market value includes the value of related goods sold by the service provider or included within the service offering. The pars planitis treatment market also includes sales of immunosuppressants, intraocular steroid implants, surgical equipment, and diagnostic tools. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pars Planitis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pars planitis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for pars planitis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pars planitis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Pars Planitis Treatment Market Characteristics

3. Pars Planitis Treatment Market Trends And Strategies

4. Pars Planitis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Pars Planitis Treatment Growth Analysis And Strategic Analysis Framework

6. Pars Planitis Treatment Market Segmentation

7. Pars Planitis Treatment Market Regional And Country Analysis

8. Asia-Pacific Pars Planitis Treatment Market

9. China Pars Planitis Treatment Market

10. India Pars Planitis Treatment Market

11. Japan Pars Planitis Treatment Market

12. Australia Pars Planitis Treatment Market

13. Indonesia Pars Planitis Treatment Market

14. South Korea Pars Planitis Treatment Market

15. Western Europe Pars Planitis Treatment Market

16. UK Pars Planitis Treatment Market

17. Germany Pars Planitis Treatment Market

18. France Pars Planitis Treatment Market

19. Italy Pars Planitis Treatment Market

20. Spain Pars Planitis Treatment Market

21. Eastern Europe Pars Planitis Treatment Market

22. Russia Pars Planitis Treatment Market

23. North America Pars Planitis Treatment Market

24. USA Pars Planitis Treatment Market

25. Canada Pars Planitis Treatment Market

26. South America Pars Planitis Treatment Market

27. Brazil Pars Planitis Treatment Market

28. Middle East Pars Planitis Treatment Market

29. Africa Pars Planitis Treatment Market

30. Pars Planitis Treatment Market Competitive Landscape And Company Profiles

31. Pars Planitis Treatment Market Other Major And Innovative Companies

32. Global Pars Planitis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pars Planitis Treatment Market

34. Recent Developments In The Pars Planitis Treatment Market

35. Pars Planitis Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기